Rolling BLA Submission Starting as Early as the End of 2018 – FDA Provides Guidance on Ongoing Requirements VANCOUVER, Washington, June 22, 2018 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that it had a productive meeting with the U.S. Food and Drug Administration (FDA) regarding the Company’s planned Biologics License Application (BLA). Based on FDA feedback, the Company will continue to gather safety and efficacy data

MINNEAPOLIS, May 31, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has launched a new website: www.precisiontherapeutics.com. This new site offers quick and easy access to essential information and features while offering a more comprehensive understanding of the Company’s value proposition and strategic direction in the precision medicine industry. It has a clean uncluttered design, improved functionality and enhanced content that better

ORLANDO, Fla., March 26, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE– Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies (IRT-103 “Lodonal™” and IRT-101″MENK”) for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDs, today announces that it has received minutes from the Type C meeting held on January 16, 2018, between Immune Therapeutics on behalf of Cytocom, the license holder, and the US Food